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Background. Nonresectable neuroendocrine tumour (NET) liver metastases respond poorly to most widely available and used
therapies. Selective Internal Radiation Therapy (SIRT) is becoming recognized as a new modality for selectively treating non-
resectable liver tumours. This paper presents an experience of 14 patients with non-resectable NET liver metastases treated with
SIRT. Methods. Between September 1997 and October 2009 14 patients with extensive NET liver metastases were treated with 2.0
to 3.0GBq of 90Yttrium microspheres. Repeat SIRT was undertaken in three patients after 16, 27, and 48 months, respectively.
Responses were assessed clinically, biochemically, and with serial CT scans. Survival was measured from initial SIRT. Results.S o m e
response was seen in all 14 patients. Carcinoid syndrome improved or resolved in 10/10 instances. 24-hour urinary 5-HIAA or
serum chromogranin A levels fell dramatically in 5/7 patients following SIRT. Serial CT scans revealed partial response or stable
disease in all 14 patients. Repeat treatment in three patients experiencing progression was associated with a further response.
Median survival after SIRT is 25 months with 6 patients being alive (and 3 patients still asymptomatic), at 19, 22, 23, 23, 58, and
60 months. Conclusions.S I R Ti sa ne ﬀective and well-tolerated treatment for non-resectable NET liver metastases capable of both
alleviating the carcinoid syndrome and achieving signiﬁcant tumour regression. Repeat treatment is an option and liver resection
after downstaging may also become possible.
1.Introduction
Gastrointestinal neuroendocrine tumours (NET), previously
known as carcinoid tumours, are rare tumours arising from
neuroendocrine cells of the digestive and respiratory tracts
with highest incidence rates being reported in black males
(4.48 per 100,000) [1]. While most are well diﬀerentiated
and relatively slow growing, they do vary considerably in
their biological behavior ranging from benign to highly
malignant. When they metastasize, they have a propensity to
spread to the liver and to present clinically with carcinoid
syndrome. The syndrome classically involves symptoms of
episodic cutaneous ﬂushing, diarrhea, bronchospasm, and,
more rarely, signs of tricuspid incompetence. Symptoms
arise in response to the systemic eﬀects of vasoactive
substances produced by the tumours which have escaped
hepaticdegradation.Inthosewithcarcinoidsyndrome,there
will usually be an elevated whole blood or platelet poor
plasma level of serotonin and an elevated 24-hour urinary
excretion of 5-hydroxyindoleacetic acid (5HIAA), which is a
metaboliteofserotonin.SerumchromograninA(CgA)levels
can also be a useful marker of the disease.
Survival and quality of life for those with NET depends
largely on the control of tumour growth and the suppression
of carcinoid symptoms. Cure is unusual because metastatic
deposits within the liver are usually widespread and seldom
permit curative resection. Conventional approaches to man-
agingthosewithNETlivermetastasesinclude(a)attemptsto
reduce tumour burden by resection, ablation, arterial emiza-
tion, or chemotherapy, (b) chemical approaches to manage
the carcinoid syndrome with somatostatin analogues, or (c)
both. These antitumour strategies have not proven terri-
bly eﬀective. The mainstay for treating widespread liver2 International Journal of Hepatology
metastases has been transarterial embolization (TAE)
or transarterial chemoembolization (TACE). While some
patients respond well to such approaches [2], the beneﬁt is
usually relatively shortlived, and there remains a need for
the development of new and more eﬀective anti tumour
strategies.Intheabsenceofparticularlyeﬀectiveantitumour
strategies most patients are simply treated with long-acting
somatostatin analogues in an eﬀort to control carcinoid
symptoms, and with the hope these may have some anti
tumour activity. However, in recent times, a variety of
newer approaches have emerged and with encouraging
beneﬁt. Peptide Receptor Radionuclide Therapy (PRRT)
with 111Indium, 90Yttrium, or 177Lutetium labeled octreotide
analogues is one such an approach [3]. Selective Internal
Radiation Therapy (SIRT) with 90Yttrium microspheres is
another and is becoming recognized as an eﬀective new tool
in the management of a number of types of advanced liver
cancer including NET [4–8].
We report our experience with fourteen patients with
NET treated with SIRT with 90Yttrium microspheres.
2. Patientsand Methods
Fourteen patients with extensive NET liver metastases, con-
sideredunsuitableforhepaticresectionorcryoablation,were
treated at the Wakeﬁeld Gastroenterology Centre during the
period from September 1997 to October 2009 and are the
subject of this report. All were treated with SIRT on one
(11 patients) or two occasions (3 patients) with or without
a period of ongoing hepatic artery chemotherapy with 5-
Fluorouracil. Prior to SIRT the patients were evaluated with
CT scans of the chest and abdomen and a variety of standard
blood tests. 24-hour urinary excretion of 5HIAA or serum
CgA was also measured serially in some patients.
SIRT involved the delivery of 2.0, 2.5 or 3GBq of
90Yttriummicrospheres(SIR-spheres,SirtexMedicalPtyLtd,
Sydney, Australia) into the hepatic artery either via a sur-
gically placed hepatic artery port-a-cath or a percutaneous
hepatic artery catheter inserted by the way of the femoral
artery. The procedure, including the choice of dose, is a
relatively straightforward one which has been described in
detailelsewhere[6].Greatcareneedstobetakentoensureall
vessels arising from the hepatic artery which feed nonhepatic
structures are either ligated or embolized. Prior to delivery
of the 90Yttrium microspheres a nuclear medicine scan is
performed in which Tc99 labeled macroaggregated albumin
(MAA) is injected into the hepatic artery to assess the likely
distribution of the 90Yttrium microspheres following their
administration. The scan provides an estimate of any liver-
lung shunt and also an indication of whether any inadvertent
delivery of 90Yttrium microspheres to foregut structures
might occur. A liver-lung shunt of greater than 12% has
been shown to be unacceptable because of the possible
development of severe radiation pneumonitis [9]. Similarly,
any indication of access to nonhepatic foregut structures
(e.g.,stomach,pancreas,orduodenum)isacontraindication
to proceeding because of the risk of severe radiation damage
to such structures. We deliver the 90Yttrium microspheres to
lightly sedated patients using a special delivery box, provided
by Sirtex Medical Pty Ltd, over a period of approximately
10 minutes. Patients generally remain in the hospital for 48
hoursfollowingSIRT.Nospecialradiationsafetyprecautions
arerequiredduringthisperiodorfollowingthereturnhome.
Tumour responses have been assessed in three ways: (a)
self-reported symptomatic improvement in symptoms of the
carcinoid syndrome, (b) serial 24-hour urinary excretion
of 5HIAA or serial serum CgA, and (c) serial CT scans
performed at 3 to 6 monthly intervals. WHO and RECIST
criteria were not used for reasons mentioned in the discus-
sion. Rather CT evidence of tumour response was deemed
to have occurred, providing index lesions reduced in size
(partial response) or did not change in size (stable disease).
Survival time is described in terms of time from SIRT.
3. Results
The fourteen patients included nine males and ﬁve females
with a mean age of 58.8 (range 29–73) years. Ten had symp-
toms of carcinoid syndrome. Patient characteristics, symp-
toms and tumour burden are shown in Table 1. Although the
primary site was not known in all cases, none of the patients
were thought to have a pancreatic primary. One patient
(patient 2) had received extensive previous treatment for
her tumour including, multiple metastasectomies and TAE.
Two patients (patient 6 and 9) were receiving long-acting
somatostatin analogue, prior to SIRT. Six patients received
whole-liver SIRT via a percutaneous hepatic artery catheter
and eight received whole-liver SIRT via a surgically placed
hepatic artery port-a-cath. The eight patients to receive
SIRT via a port-a-cath also received ongoing hepatic artery
chemotherapy with 5FU (4g every 4-weeks by continuous
infusion over 4 days). In seven of the patients, this was given
for between 6 and 12 cycles, but in the 8th it was given
for only two cycles because of technical failure of the port.
Three patients (patients 1, 5, and 6) had a repeat treatment
with SIRT, 16, 27, and 48 months after the ﬁrst treatment
respectively. In all three patients the ﬁrst SIRT had resulted
in an excellent response and each experienced a further good
response following the second SIRT. The others either had
extrahepatic metastases at the time of liver progression or
did not seek further SIRT. Patient 6 underwent a palliative
extended right hepatectomy, some16 months afterher initial
SIRT and some 28 months before her second SIRT. She died
79 months after the ﬁrst SIRT with bony metastases and
minimal liver disease.
There were no-treatment-related deaths or serious com-
plications following either surgery or the SIRT. The SIRT
was followed for some weeks with anorexia and lethargy in
all patients but was otherwise well tolerated. In particular,
there were no instances of early radiation hepatitis, radia-
tion pneumonitis, or radiation gastritis. All patients were
discharged within 48 hours of receiving SIRT. One patient
(patient 5) developed slow and late signs of non-icteric liver
failure and died 10 months after his second SIRT (37 months
after his ﬁrst SIRT). The cause of death was not clear but was
not obviously related to the SIRT or tumour burden.International Journal of Hepatology 3
Table 1: Patient details and response to selective internal radiation therapy.
Patient Gender Age Carcinoid syndrome Liver Involvement 5HIAA response CT response Survival (months)
1∗ Male 29 Yes 25–50% Yes Yes 34.2†
2 Female 49 Yes >50% n/a Yes 26.9†
3M a l e 7 0 N o >50% n/a Yes 11.9†
4 Male 64 Yes <25% Yes Yes 110†
5∗ Male 71 Yes <25% Yes Yes 37†
6∗ Female 46 Yes >50% Yes Yes 79†
7∗ Female 60 No <25% n/a Yes 60
8M a l e 5 2 N o <25% n/a Yes 58
9 Male 61 Yes 50% n/a Yes 16.4†
10∗ Female 60 Yes 25–50% No Yes 21†
11∗ Male 72 Yes <25% Yes Yes 23
12∗ Male 60 No <25% Yes Yes 23
13∗ Male 56 Yes <25% n/a Yes 22
14 Female 73 Yes <25% n/a Yes 19
†Deceased; ∗received hepatic artery chemotherapy.
Table 1 documents the responses noted in the fourteen
patients. Carcinoid syndrome resolved or improved in all
ten patients and a CT response (regression or stable disease)
w a ss e e ni na l lf o u r t e e np a t i e n t s .T h eC Ts c a n sb e f o r ea n d
after SIRT in patients 4 and 6 are shown in Figure 1. 24-
hour urinary excretion of 5HIAA or serum chromogranin A
levels fell in 6/7 patients in whom it was serially measured as
shown in Figure 2. The fall was dramatic in ﬁve of the seven
patients and was well maintained in all ﬁve. Median survival
aftertheﬁrstSIRTis25monthswith6patientsstillalive(and
3 patients being asymptomatic), at 19, 22, 23, 23, 58, and 60
months.
Performance status as assessed by Karnofsky score was
improved in all but one patient with advanced disease who
did not do well following SIRT, despite CT evidence of a
response. Mean Karnofsky scores improved from a value of
86.5 prior to SIRT to 93.5, 3–6 months following SIRT.
4. Discussion
Although the natural history of NET is generally regarded
as relatively benign, metastatic disease does develop in a
proportion of those aﬀected. In a large study of 13715
carcinoid tumours from US databases some 12.7% had
metastases at presentation [1] and a similar ﬁgure was
reported from the ERG database of 2837 individuals [10].
Furthermore, while those with metastatic NET do have a
more favorable prognosis than those with most other types
of metastatic tumours, cure remains extremely unusual.
Thus, although 5-year survival following recognition of liver
metastases is achieved by some, most will succumb from the
disease in this timeframe. Godwin reporting on the large
ERG database noted that the 5-year survival for patients
with distant spread from NET was only 18%. Another more
recent report showed mean survival of those with carcinoid
syndrome at only 38 months [11].
The use of regular long-acting somatostatin analogues
has had an important and signiﬁcant impact on the man-
agement of both functioning and nonfunctioning NET.
The analogues octreotide and lanreotide are now widely
used to control symptoms in those with symptomatic NET
tumours and excellent control can be expected in around
75% of patients, although escalating doses may be required.
Patients with symptoms refractory to one formulation may
respond to another [12]. Biochemical responses are also
seen with the somatostatin analogues but less often (i.e.,
40–50%) than the symptomatic responses [13]. There is
recent data from the PROMID trial and others that long-
term use of octreotide LAR appears to have anti tumour
eﬀects which may stabilize disease or even achieve partial
regression [14]. Previous reports have also suggested that
tumour regression or stability can be achieved by use of
somatostatin analogues alone [15, 16]. In the PROMID trial
the anti tumour eﬀects seemed to be most pronounced
in those with low-volume hepatic disease. For all of these
reasons, somatostatin analogues have become central in the
contemporary treatment of metastatic NET.
Anti tumour approaches have involved a variety of
modalities over the years with varying, but not usually
predictable or reliable beneﬁt. These include systemic
chemotherapy, TAE, TACE, and a variety of locally ablative
therapies. Although systemic chemotherapy is commonly
administered, particularly in symptomatic patients with
advancing disease, results are generally disappointing. Many
diﬀerent agents including doxorubicin, 5-ﬂuorouracil, strep-
tozotocin, mitotane, docetaxel [17–19], topotecan, lomus-
tine, and leucovorin with or without interferon alpha have
been used but none have delivered response rates exceeding
15–20%, and generally only for short periods. Survival
advantage is doubtful or small [20–23].
TAE and TACE protocols have been widely employed
and can certainly achieve symptomatic and biochemical
responses with tumour regression in many patients. Such
responses may be seen in as many as 65% of instances [17–
19], but are seldom sustained. Touzios et al. have reported
that aggressive management of patients with carcinoid
syndrome with chemotherapy, embolization, and locally
ablative surgery or radiofrequency ablation can improve4 International Journal of Hepatology
9cm
0cm
(a) (b)
0
L
R
5
cm
120kV
130m
2s e c
A
(c)
0
10
cm
L
48cm
0cm
(d)
Figure 1: CT scans before and after SIRT. (a) patient 4 prior to SIRT, (b) patient 4 four years following SIRT, (c) patient 6 prior to SIRT, (d)
patient 6 three months following SIRT.
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Figure 2:Graphicrepresentationofserial24hrurinaryexcretionof
5HIAA or serum chromogranin in seven patients. Pre-SIRT values
have been normalized to 1.0.
mean survival for this group to around 50 months with a
5-year survival to around 48% [24].
Peptide Receptor Radionuclide Therapy (PRRT) using a
variety of radionuclide-(111Indium, 90Yttrium, or 177Luteti-
um) labeled octreotide analogues has attracted growing
interest in recent years [25] and is being actively investigated
in many centres around the world. 90Yttrium or 177Lutetium
appear more eﬀective radionuclides because of higher energy
and therefore greater tumour penetration. Symptomatic and
biochemical responses are seen in a variable proportion
of patients and partial response or stable disease are seen
in up to 50% of subjects, at least for a period [26–29].
Renal, bone marrow, and hepatic toxicity have been a
problem, but are becoming less so with use of alternative
analogues and concomitant renal protection. Furthermore,
a variety of diﬀerent octreotide analogues are under in-
vestigation, in an eﬀort to improve the aﬃnity for the
somatostatin receptors, and thereby the therapeutic index. It
has been suggested, but not, established, that PRRT is more
useful in managing small tumours [30]. However, only those
patients with high aﬃnity for the relevant analogue, shown
by scintigraphy, are candidates for such therapy.
An alternative approach to targeted radiotherapy is
Selective Internal Radiation Therapy (SIRT) using hepatic
arterial delivery of 90Yttrium microspheres as described in
the present study. In our experience, we saw a response in
all of our patients, based on symptomatic beneﬁt (10/10),
biochemical measurement (6/7), and at least stable disease
on CT scanning (14/14). This was achieved without serious
or signiﬁcant toxicity. Median survival after the ﬁrst SIRT
is 25 months which compares favourably with alternative
therapies. Furthermore, six patients are still alive at 19, 22,
23, 23, 58, and 60 months, with three being asymptomatic.
Hepatic arterial delivery of the microspheres delivers
high doses of high-energy β radiation to liver tumours,
with relative sparing of normal hepatic parenchyma. SIRTInternational Journal of Hepatology 5
with 90Yttrium microspheres is emerging as a very eﬀective
modality for treating nonresectable secondary and primary
liver tumours [4, 31–37] with many reports attesting to
response rates of 80% and greater for both metastatic
colorectal cancer and hepatocellular cancer. This particu-
lar vehicle for 90Yttrium delivery has the advantage over
octreotide analogues that it does not depend on the presence
of somatostatin receptors, and it has a higher-therapeutic
index. Furthermore, providing the SIRT is administered
appropriately, there is a very low risk of extrahepatic toxicity,
despite high doses being delivered. However, because the
therapy is delivered via the hepatic artery, it is only suitable
forliver-onlyorliver-predominantmetastaticdisease.Bythis
technique, average doses of absorbed radiation by tumour
are in the range 150–250Gy while normal liver parenchyma
receives average doses in the range 15–25Gy, which are
well tolerated by the liver [4, 38–40]. The principal adverse
eﬀect of SIRT relates to gastroduodenal ulceration from
inadvertent delivery of microspheres to these structures
which may occur in up to 5–10% of patients, depending on
method of arterial delivery [33]. Fatal radiation hepatitis or
radiation pneumonitis is very rarely seen with appropriate
selection of cases and currently used dosing schedules.
We have previously conducted and published a study
evaluating the utility of changes in tumour size (e.g., WHO
and RECIST criteria) as a means to determine response fol-
lowing SIRT. In that study we demonstrated that changes in
size, as conventionally assessed following chemotherapy are
a very unreliable indicator of response to SIRT. We demon-
stratedandbelievethatprovidingtumoursdonotincreasein
size following SIRT, a response is likely to have occurred, and
that tumour marker data, when available, is the most reliable
and immediate indicator of response to therapy [41]. Based
on this method of assessing response, all 14 of our patients
with NET liver metastases responded positively to SIRT,
a n dm o s tf o rap r o t r a c t e dp e r i o do ft i m e .W h i l ei ts e e m s
unlikely such a high response rate will be observed when
larger numbers of patients are treated, the results certainly
point to this being a valuable new treatment option.
At least three other reports of SIRT in metastatic NET
tumours have been published and a number of other groups
throughout the World have been using this approach with
good results [7, 8, 42] .I nar e p o r to n3 4p a t i e n t sf r o m
Australia, a symptomatic response was observed in 55% at
3 months and 50% at 6 months. Radiologic liver responses
by RECIST criteria were observed in 50% of patients and
included18%completeresponsesand32%partialresponses.
The mean overall survival was 29.4 ± 3.4 months [7]. In
the second report from a number of contributing centres in
the US, imaging revealed complete response in 2.7%, partial
responsein60.5%,andstablediseasein22.7%withamedian
survival of 70 months [8] .I nar e p o r to n1 0p a t i e n t sf r o m
T u r k e yar e s p o n s er a t eo f9 0 %w a sr e p o r t e d[ 42].
Our preference has been to deliver 90Yttrium micro-
spheres through a surgically implanted port in the hepatic
artery because, in our experience, this permits whole-liver
delivery of 90Yttrium microspheres with less likelihood of
gastro-duodenal ulceration than delivery through a percu-
taneous catheter because of the opportunity surgery presents
for ligation of small arteries passing from the hepatic artery
to the gastroduodenum [33]. In patients with a port, we also
aim to follow the SIRT with 12 months of hepatic artery
chemotherapy using 5FU, as described for some patients in
this report. While there is no clear evidence that this adds
value to the SIRT in the setting of NET, it is accomplished
with minimal, if any, side eﬀects and may contribute to
maintenance of a response.
5. Conclusion
AlthoughmetastaticNETisoftenthoughtofashavingaslow
natural history, active treatment is desirable, particularly in
the presence of progressive disease or carcinoid syndrome.
While a number of options including chemotherapy, TAE,
TACE, and, more recently, PRRT have been used with some
success, SIRT with 90Yttrium microspheres is an emerging,
simple, and eﬀective alternative for selectively delivering
radiotherapy to liver metastases. Our experience, and that
of others, suggests this may be the treatment of choice
for liver-only or liver-predominant NET. The time may be
approaching for conducting a multicentre randomised trial
comparing SIRT with TACE.
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